Certified by Founder
Lodge
Tome Biosciences
start up
United States
- Watertown, Massachusetts
- 14/12/2023
- Series B
- $213,000,000
Tome Biosciences is the programmable genomic integration (PGI) company. Our technologies allow us to insert any genetic sequence of any size at any location in the genome with site-specific precision. We are writing the final chapter in genomic medicines, delivering cures to patients through cell and integrative gene therapies.
- Industry Biotechnology Research
- Website https://tome.bio/
- LinkedIn https://www.linkedin.com/company/tome-biosciences/about/
SavvyMoney | $225,000,000 | (Oct 28, 2025)
Paygentic | $2,000,000 | (Oct 28, 2025)
Honey Health | $7,800,000 | (Oct 28, 2025)
Natural | $9,800,000 | (Oct 28, 2025)
PodPlay Technologies | $8,000,000 | (Oct 28, 2025)
Seneca | $60,000,000 | (Oct 28, 2025)
Serval | $47,000,000 | (Oct 28, 2025)
Bridge(US) | $5,100,000 | (Oct 28, 2025)
Vermeer | $10,000,000 | (Oct 24, 2025)
GammaTime | $14,000,000 | (Oct 24, 2025)
Apriority Financial, Inc. | $2,300,000 | (Oct 24, 2025)
GradBridge | $20,000,000 | (Oct 24, 2025)